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Due in part to the introduction of peripheral blood progenitor cells
(PBPCs) as a source of haematopoietic support, administration of
high-dose chemotherapy in the treatment of solid tumours has
been increasingly studied in recent years. Uncontrolled phase I and
II studies of high-dose chemotherapy in metastatic breast cancer
have suggested a possible increase in the percentage of patients
who achieved a durable complete remission (Antman et al, 1997;
Basade and Gulati, 1998; Zujewski et al, 1998). So far, only one
small randomized Phase III trial has been published to support this
improvement (Bezwoda et al, 1995) but final results of currently
ongoing phase III studies of high-dose chemotherapy in high-
risk primary and metastatic breast cancer are eagerly awaited.
Expectations are however that whereas a small proportion of
patients with metastatic breast cancer may benefit from intensive
treatment, the majority will have resistant disease and will
continue to relapse rapidly. Immunomodulation strategies, which
might be non-cross resistant with high-dose chemotherapy (Fuchs
et al, 1995), could provide a way to overcome chemotherapy-
resistant cell-clones. In patients with acute myeloid leukaemia, the
occurrence of GVHD following allogeneic bone marrow trans-
plantation has been associated with a prolonged disease-free
survival whereas use of an autologous graft to avoid GVHD-
related morbidity resulted in increased relapse rates (Weiden et al,
1980). 
Administration of Cyclosporine, CsA, a drug that influences the
redeveloping immune system following syngeneic or autologous
BMT, induces an auto-aggression syndrome with pathology iden-
tical to allogeneic GVHD (Glazier et al, 1983; Cooper et al, 1991).
In this respect, Cyclosporine, known as an effective immuno-
suppressive drug (Kahan, 1982) is the agent most extensively evalu-
ated for the induction of autologous (in human) or syngeneic (in 
rat) GVHD. CsA which inhibits thymic-dependent clonal deletion
induces release of CD8+ autoreactive T-cells that promiscuously
recognize MHC class II determinants on syngeneic and MHC
disparate cells (Hess et al, 1990; Fischer et al, 1995; Ruvolo et al,
1995). Critical for the induction of this autoaggression syndrome is
the elimination of a peripheral regulatory mechanism that controls
the autoreactive T cells (Fischer et al, 1995). Elimination of the
regulatory T cells by the preparative regimen provides a permissive
environment for the autoreactive T cells to manifest autoaggression.
The first clinical study to suggest an antitumour effect of CsA
induced GVHD following autologous BMT (auBMT) in humans
was in lymphoma patients (Jones et al, 1989). The occurrence of
GVHD was found to be associated with the presence of autoreactive
T-cells directed against MHC class II (HLA-DR) antigen. Since
breast cancer cells have been reported to bear HLA-DR antigen
(Bartek et al, 1987; Whitford et al, 1992), similar studies were initi-
ated in women undergoing auBMT for metastatic breast cancer
(Kennedy et al, 1993, 1994). Autologous GVHD could be induced
concurrent with the development of α /β TcR-postive CD8+ auto-
reactive effector cells in the peripheral blood (Hess et al, 1997). 
The use of PBPCs following high-dose chemotherapy has accel-
erated haematopoietic recovery thereby decreasing the number of
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a PBPC-graft contains significantly more T-cells when compared
to bone marrow, transfer of these T cells might restore the
peripheral auto-regulatory mechanisms that impair the auto-
reactive T-cells and, as a consequence, the induction of GVHD
could be significantly reduced. 
The present study aimed to define the influence of stem cell
grafts on PBPCs stem cell grafts on the induction of autologous
GVHD following high-dose chemotherapy. After high-dose
alkylator chemotherapy, patients with stage III or IV breast cancer
received either PBPCs alone or PBPCs with auBMT for haemato-
poietic rescue. Subsequently, patients were given CsA and IFN-γ
to induce autologous GVHD. The administered dosages of CsA
and IFN-γ given were in accordance with the doses as defined in
the previous phase I study (Kennedy et al, 1994). Induction of
GVHD was determined by clinical evaluation, evaluation of skin
biopsies and lymphocyte-cytotoxicity assays using autologous
pre-transplant PHA-lymphoblasts and 2 different pre-defined cell-
lines. The incidence and degree of GVHD was compared with that
observed in a prior study in which patients underwent high-dose
chemotherapy supported with bone marrow alone (Kennedy et al,
1994). 
MATERIALS AND METHODS 
Patients
Women between the ages of 18 and 60 years with a ECOG perfor-
mance status of <2 with histologically documented breast cancer
which had metastasized or was either inoperable or locally re-
current were eligible. A minimum of 2 cycles of standard dose 
systemic chemotherapy without evidence of progressive disease
preceded study entry. 
Any oestrogen or progesterone receptor level was allowed. The
renal, cardiac, pulmonary and haematopoietic reserves had to be
adequate to undergo high-dose alkylator therapy. All patients had
bone marrow biopsies that were negative for tumour by routine
histologic examination. 
Conduct of the trial was approved by the Joint Committee on
Clinical Investigation of the Johns Hopkins Hospital. All patients
provided informed written consent. 
High-dose chemotherapy and PBPC-T/BMT
PBPCs were mobilized following the subcutaneous (s.c.) adminis-
tration of G-CSF at 5 µ g kg day–1 for 5 consecutive days, starting
at the day of the bone marrow harvest. On the 6th day a 6-hour
long high-blood flow leukocytophoresis was performed using a
COBE Spectra apheresis machine, as previously described (Passos-
Coehlo et al, 1995). In the first 18 patients bone marrow (3 × 108
cells) was also collected, 4–6 weeks after administration of the last
cycle of standard dose chemotherapy, and routinely reinfused the
day following PBPC-reinfusion. In the remaining patients, bone
marrow was collected only when less than 3 × 106 CD34+
PBPC kg–1 were harvested, which occurred in 10 patients. PBPCs
were reinfused on day –1, two days after the end of high-dose
chemotherapy. Marrow, if administered, was reinfused on day 0. 
With a minimum of at least 5 days after the last dose of 
G-CSF for PBPC-mobilization, patients began high-dose
chemotherapy with cyclophosphamide (Cytoxan) 1.5 g/m2/day, in
250 ml D5 by continuous infusion (CI) and thiotepa (N,N′ N″ -
triethylenethiophosphoramide) 200 mg/m2/day in 500 ml D5 CI,
both for 4 days (days –8 to –4). The high-dose chemotherapy and
supportive care treatment was administered as previously 
described (Kennedy et al, 1994). 
Autologous GVHD induction 
Cyclosporine (CsA) administration at 2.5 mg kg–1 ideal body-
weight day–1 i.v. over 4 hours in 2 divided doses was initiated on
day 0, to be continued for 28 days. Patients who were discharged
before day 28 received CsA orally at a dose 4 times the i.v. dose
given in 2 divided doses while whole blood levels were monitored.
The oral dosage was increased 25% if levels were below
200 ng ml–1. CsA dosing was modified for renal toxicity as
described previously (Kennedy et al, 1994). 
IFN-γ (provided by: Cancer Therapy Evaluation Program,
Division of Cancer Treatment, National Cancer Institute) was
administered daily at a dose of 0.025 mg/m2 s.c., starting at day 
+7 through day +28. The only dose modification of IFN-γ was
complete discontinuation of therapy for reasons of toxicity or
severe GVHD, i.e. stage III rash covering more than 50% of the
patients body (Glucksberg et al, 1974) and a skin biopsy diag-
nostic of >grade II GVHD (Sale et al, 1977). 
Treatment of GVHD was begun when patients developed symp-
tomatic skin GVHD and consisted of topical steroids and systemic
antihistamines followed by untimely discontinuation of CsA. If
ineffective or in case of visceral GVHD systemic prednisone i.v.
was initiated and readily tapered upon clinical improvement. 
Evaluation of toxicity and immune reactivity 
Patients were examined daily for evidence of rash, jaundice, and
diarrhoea. Daily monitoring of serum chemistries, complete blood
cell count and stool volume was undertaken. In addition, the 
time to platelet and WBC recovery and the incidence of non-
haematological toxicities were prospectively monitored in each
patient. 4-mm punch biopsies of skin were performed before start
of high-dose chemotherapy (day –9), and on days +14 and +35 and
at any other time GVHD was clinically suspected. Each biopsy
was examined under light microscopy in a blinded fashion by one
of the investigators (TH) who was unaware of the patients’ clinical
status. Haematoxylin-stained sections were graded for GVHD by
previous published criteria (Bauer et al, 1993; Horn et al, 1994). 
50 millilitres of peripheral blood were collected prior to high-
dose chemotherapy (HDC) and on days +5, +12, +19, +26 and 
+33 for analysis of lymphocyte-mediated cytotoxicity by utilizing
the 51Cr release assays (Hess et al, 1997). Peripheral blood mono-
nuclear cells were isolated by Ficoll-Hypaque density centrifuga-
tion, washed in RPMI-1640, and resuspended in complete culture
medium consisting of RPMI-1640, 10% fetal calf serum, 1% glut-
amine, 100 u ml–1 penicillin and 100 µ g ml–1 streptomycin. 
The lymphocytes were quantitatively tested for NK-cell func-
tion using the K562 cell line while MHC class II specific lytic
activity was assessed by evaluating the ability of the lymphocytes
to lyse autologous phytohaemagglutinin (PHA) stimulated lympho-
blasts, cryopreserved prior to transplant. In addition, the MHC
class II positive breast cancer cell line T47D, pre-incubated for
1 hour at 4˚C in normal mouse serum (0.1% in RPMI-1640) or
murine monoclonal antibody to HLA-DR (1:50 dilution in RPMI-
1640) were used as target cells. Based on previous studies of au
BMT recipients not treated with CsA, and patients tested prior to
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cytes was considered indicative of autocytolytic activity. 
Target and K562 cells were washed in RPMI-1640 and labelled
with 100–200 µ Ci of 51Cr for 18 hours whereas T47D cells were
plated at 3000 cells well–1 in 200 µ l plates and pulsed with 1–2 µ Ci
of  51Cr for 18 hours as previously described (Hess et al, 1997). 
All target cells subsequently were washed in RPMI-1640 and re-
suspended in complete culture media. Effector and target cells
were incubated in or triplicate wells at ratios of 100:1, 50:1 and
25:1 in a total volume of 0.2 ml for 4 hours. Supernatants 
were analysed on a γ -Coulter (Miniaxi γ , Packard Instruments
Company, Downers Grove, IL) where maximum and spontaneous
51Cr release was calculated according to the following formula: 
% specific 51Cr release = (cpm experimental – cpm spontaneous) 
× 100/(cpm maximum – cpm spontaneous). The variability
between replicate cultures oversized less than 10%. 
Statistical evaluation 
The association between the induction of GVHD and each of the
variables of interest was measured using chi-square and/or
Fisher’s exact tests. Univariate logistic regressions were used to
obtain the odds ratio and to test the significance of the association
between GVHD and each of the continuous variables. 
To compare DFS and OS for the binary or categorical variables
of interest, Kaplan–Meier estimates and graphs were obtained.
Log-rank tests were performed to test the equality of the survival
functions across the groups. For the continuous variables, Cox
regression analyses were used to examine the association between
DFS, OS and each of the variables presented.
RESULTS 
Patient characteristics 
From 2/25/1994 until 11/8/1995, 50 patients were enrolled in the
protocol with a median time to follow-up (TTFup) of 29.4 months
(range 1.3–47.7). 
As shown in Table 1, when divided according to means of
haematopoietic support, both groups of patients were equally
matched with regard to pertinent patient characteristics, i.e. age,
performance status, stage of disease and hormone-receptor status. 
GVHD 
Induction of autologous GVHD, defined as having skin-biopsy
grade II or more (Bauer et al, 1993; Horn et al, 1994), was observed
in 18 patients (36%), equally distributed over both groups of
haematopoietic support (Table 1). Predictive characteristics for the
development of GVHD grade II could not be defined (Table 2). 
Two patients, in whom skin-biopsies revealed GVHD grade II,
were diagnosed with subclinical GVHD. In 8 patients, the symp-
toms of GVHD required treatment with systemic corticosteroids.
All of these patients were diagnosed, usually in the 3rd–4th week
following PBPC-T ± BMT, with a stage III skin-rash and were
observed at histological examination to have grade II GVHD. The
length of corticosteroid administration varied from 15 days to 
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Table 1 Patient characteristics 
All patients (n = 50) PBPCS + BM (n = 28)  PBPCS (n = 22) 
BX grade ≥ 2  (18) 36 (10) 36 (8) 36 
(no.) % pos.
AGE years
Mean (range) 45 (28–61) 46 (28–61) 46 (29–60) 
PS (no.)% 
0 (34) 68 (20) 71 (14) 64 
1 (16) 32 (8) 29 (8) 36 
STAGE (no.)% 
III B (15) 30 (9) 32 (6) 27 
IV (35) 70 (19) 68 (16) 73 
Visceral: (9) 26 (5) 26 (4) 25 
Bone: (14) 40 (8) 42 (6) 37.5 
Locoregional: (12) 34 (6) 32 (6) 37.5 
RECEPTOR (no.)%* 
ER + (22) 44 (10) 36 (12) 54 
PR + (20) 40 (11) 39 (9) 41 
Unknown (both) (8) 16 (5) 18 (3) 14 
DFS (no.)% (13) 26 (7) 25 (6) 27 
OS (no.)% (29) 58 (16) 57 (13) 59 
DOD (no.)% (20) 40# (11) 39# (9) 41 
TTprog months 
Median (range) 17 (0.8–47.7) 16.5 (0.8–47.7)  18.2 (1.4–38.5) 
TTFup months 
Median (range) 29.4 (1.3–47.7) 31.9 (1.3–47.7)  29.1 (7.5–40) 
PBPCS = peripheral blood progenitor cell support, BM = bone marrow, ER = oestrogen receptor, 
PR = progesteron receptor, GVHD = autologous graft versus-host disease, BX = biopsy, TTFup = time to follow-
up, TTprog = time to progression, DFS = disease free survival, OS = overall survival, DOD = dead of disease. 
*Positive = ≥ 10 fmol mg–1 cytosolic protein. # 1 patient died of CMV-infection.2   months. In 2 of the patients with biopsy-proven grade II GVHD
of the skin, intestinal GVHD developed. Presenting symptoms of
frequent diarrhoea and abdominal cramping were rapidly resolved
by the administration of methylprednisolone i.v. in one patient.
However, in the second patient, apparent chronic GVHD developed
with a persistent malabsorption diarrhoea, abdominal cramping and
fluctuating periods of nausea and vomiting. A small bowel follow-
through showed skip areas of fibrosis and stenosis consistent with a
GVHD-like process, which was confirmed by histological exami-
nation. Before the diagnosis of intestinal GVHD was made, the
patient had already received methylprednisolone i.v. for her clinical
stage III, histological grade II cutaneous GVHD. Increasing the
dose of systemic corticosteroids did not improve the abdominal
complaints. FK 506 was added but had to be discontinued after
1 week because of associated fevers. Subsequently oral CsA,
2.25 mg b.i.d. was initiated which reduced the severity of the
intestinal symptoms. Both the methylprednisolone and the CsA
were continued until shortly before her death. The patient devel-
oped pneumonia, shortly after analysis of her serum had shown
signs of an active CMV-infection. Despite vigorous and appropriate
systemic therapy the patient died of respiratory failure. 
In the 8 patients in whom systemic treatment with cortico-
steroids was required, the lymphocytotoxicity data were not
indicative of a more serious course of the GVHD when compared
to the results of all GVHD-patients (Table 3). 
Lymphocytotoxicity analysis
Lymphocytes from the patients were assessed temporarily post-
transplant for their ability to lyse pre-transplant lymphoblasts and
the breast cancer cell line T47D. NK activity was also assessed
utilizing the NK target cell line, K562. Representative experiments
evaluating lymphocytotoxicity for 4 patients are shown in 
Figures 1A, B, C, D demonstrating the temporal development of
autocytolytic activity. Two of the patients developed auto-GVHD
(A, C) while the other two did not (B, D). Autocytolytic activity
developed while the patients were on CsA but did not correlate
with the development of auto-GVHD. Figures 2 A, B presents the
autocytolytic activity for patients who developed auto-GVHD (A)
and for those who did not develop this syndrome. One apparent
difference between groups is that the autocytolytic activity in the
patients with auto-GVHD appeared to develop later and persisted.
This lytic activity could be detected early in the patients without
auto-GVHD but waned quickly. The composite data analysing
maximum lytic activity and time to this event are summarized in
Table 3. Autocytolytic activity could be detected in 76% of all
patients. Although not significant, there was a difference in median
percentage cytolytic activity against autologous PHA-lymphoblasts
between the patients who had developed GVHD and those who had
not, being higher in the first group. Of interest, the day to maximum
autocytolytic activity was delayed for the patients with GVHD
compared to those patients who did not develop this autoaggression
syndrome. Lymphocytes from the tested post-transplant also devel-
oped the ability to effectively lyse the T47D, MHC class II positive
breast cancer cell line. Previous studies demonstrate that recogni-
tion of this cell line and the autologous lymphoblasts in the auto
GVHD setting is MHC class II-dependent since pretreatment of the
target cells with monoclonal antibody to MHC class II but not
MHC class I determinants blocked lysis (Hess et al, 1997).
Interestingly, the cytotoxic activity against the T47D cell line by
the post-transplant lymphocytes of the patients with cutaneous
GVHD grade II was significantly enhanced when compared with
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Table 2 Patient characteristics according to GVHD-status 
GVHD >1 (n = 18) GVHD 0 +1 (n = 32) 
NO. OF PBPC mean (range) 
CD34 × 106/kg 6. (0.5–20.5) 4.7 (1.0–16) 
AGE mean (range) 48 (38–59) 44 (28–61) 
PS (no.)% 
0 (13) 72 (19) 59 
1 (5) 28 (13) 41 
STAGE (no.)% 
IIIB (4) 22 (11) 34 
IV (14) 78 (21) 67 
TTFup months 
Median (range) 34.6 (6.9–47.6) 29.1 (1.3–47.7) 
DFS (no.) % (3) 17 (10) 31 
OS (no.) % (11) 61 (18) 56 
DOD (no.) % (6) 30* (14) 44 
TTprog months 
Median (range) 16.5 (3.7–47.6) 17.2 (0.8–47.7) 
WBC >1000 days 
Median (range) 12.5 (10–22) 12 (8–24) 
PLAT TI days 
Median (range) 9 (5–26) 8 (5–39) 
GVHD = autologous graft-versus-host disease, PBPC = peripheral blood progenitor
cells, PS = performance status, TTFup = time to follow-up, DFS = disease free
survival, OS = overall survival, DOD = dead of disease, TTprog = time to progression,
WBC >1000 = white blood cell count >1000 × 106/L, plat TI = days to platelet
transfusion independence. *1 patient died of CMV-pneumonia.
1
2patients without GVHD (P = 0.0236). NK activity was also
enhanced in this group of patients. If the lymphocytotoxicity values
were taken as independent variables, only the percentage cell-kill of
the T47D breast cancer cell-line was predictive of who would
develop cutaneous GVHD grade II, P = 0.024 (data not shown). 
Survival data 
With a median time to follow-up of 29.4 months (range 1.4–47.7)
from time of PBPC-T ± BMT, the OS for all patients is 58%. The
DFS is 26% whereas 16 patients (32%) are alive with disease 
with a median time to progression of 17 months (range 0.8–47.7)
(Table 1). A number of well-known prognostic factors proved also
to have a significant influence on the survival parameters in this
study, i.e. stage of the disease, number of metastatic sites and
skeletal involvement and whether patients received high-dose
chemotherapy for recurrent disease or at first presentation. When
patients were divided according to their GVHD-status, however,
no significant differences could be demonstrated with regard to
outcome (Table 2). 
Toxicity 
CsA was discontinued early in 2 patients for reasons for nausea
and vomiting in one and a change in liver-function in the second
Peripheral blood stem cells and autologous GVHD for breast cancer 1409
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Table 3 Lymphocytotoxicity analysis for all patients (percentage cell-kill by post-transplant lymphocytes) 
ALL (n = 50) GVHD (n = 18) No GVHD (n = 32) 
PHA-lymphoblasts, median (range) 8.4 (4–43.7) 11.3 (0.8–25.2) 6.6 (0.4–43.7) 
Day max, median (range) 13 (5–33) 19 (5–33) 12 (5–33) 
Patients (n) 49 17 32 
PO. Patients > 3.5% kill 37 13 24 
T47D, median (range) 20.1 (7.4–57.1) 30.3 (7.4–53.7)** 18.3 (8–57.1) 
Day max, median (range) 19 (5–33) 19 (5–33) 19 (5–33) 
Patients (n) 39 11 28 
K 562, median (range) 56.5 (28.2–100) 60.4 (42.4–76.2)* 52.35 (28.2–100) 
Day max, med (range) 19 (5–33) 26 (5–33)  19 (5–34) 
Patients (n) 49 17 32 
Wilcoxon: *P = 0.0395; **P = 0.0236. Lytic activity in peripheral blood lymphocytes was assessed post high dose
chemotherapy and PBPC rescue. Maximum lysis (at a 100:1 effector:target ratio) of autologous lymphoblasts,
T47D cells and the NK target K562 cells and time to maximum lysis were assessed lysis autologous
lymphoblasts exceeding 3.5% was considered for autocytolytic activity. This cutoff value was determined
evaluating control (non-CsA) au BMT patients.
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Figure 1 Temporal assessment of lymphocytotoxicity post Au BMT and CsA
treatment. Data (mean ± S.E.M.) represent lytic activity measured against
autologous lymphoblasts, T47D cell line and the NK target, K562 at 100:1
effector:target ratio 
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Figure 2 Temporal assessment of autocytolytic activity for patients
developing autologous GVHD (A) and for those who did not (B). Data
represent lysis of pretransplant autologous lymphoblasts at a 100:1
effector:target ratiopatient. In one patient a mild hypertension developed after admin-
istration of CsA, which was resolved by adding a calcium-channel
blocker. Mucositis was diagnosed in 24/39 patients, and more than
grade II in 10. One patient died of a (presumed) pulmonary CMV
infection, as described earlier; otherwise, no serious infectious or
septic episodes were recorded. 
DISCUSSION 
Previous studies have shown that autologous GVHD could be
induced in women with advanced breast cancer by the administra-
tion of high-dose chemotherapy followed by CsA (Kennedy et al,
1993) or CsA and IFNγ (Kennedy et al, 1994). In both studies,
haematopoietic support was provided by autologous bone marrow.
Moreover, the induction of this syndrome was associated with the
development of CD8+ autoreactive T cells that promiscuously
recognize MHC class II antigens and could lyse MHC class II
positive breast cancer cells (Hess et al, 1997). Promiscuous recog-
nition of MHC class II was dependent on presentation of a peptide
from the invariant chain peptide CLIP, with a superagonistic inter-
action between the N-terminal fragment of the peptide and the Vβ
component of the T cell receptor (Hess et al, 1997, 1998). As
PBPCs have replaced BM as the source of haematopoietic support,
the current phase II study was designed to establish whether the
use of PBPCs would affect the incidence of GVHD. 
The results from the present studies suggest that there is a
reduced incidence of autologous GVHD, defined as ≥ grade II 
on skin biopsy (Bauer et al, 1993; Horn et al, 1994), in patients
receiving PBPCs. In a previous phase I study, a 59% incidence of
GVHD grade II was reported (Kennedy et al, 1994) compared to
36% observed in the present report. No difference in the induction
of GVHD could be attributed to means of haematopoietic support,
i.e. PBPCs alone or in combination with BM. 
One possibility that might account for the decreased incidence
of GVHD observed in the present study is the more strict defini-
tion of grade II histopathological cutaneous GVHD. In the present
study, cutaneous GVHD ≥ grade II required not only the presence
of necrotic keratinocytes and satellite cell necrosis, as was used in
the phase I study, but also significant lymphoid infiltration of the
dermis. Dyskeratotic keratinocytes and satellite cell necrosis may
be insufficient to make a histologic differentiation between erup-
tions of lymphocyte recovery and GVHD (Bauer et al, 1993; Horn
et al, 1994). 
On the other hand, PBPCs contain large number of T lympho-
cytes that may have regulatory potential. Studies in the animal of
auto-GVHD indicate that transfer of even relatively small numbers
of T lymphocytes was sufficient to inhibit the induction of this
autoaggression syndrome (Fischer and Hess, 1990). Of additional
interest in this regard is a recent report by Miura et al (2000).
Autologous GVHD could not be induced in patients receiving
PBPCs unless the T lymphocytes were removed. It is important to
note, however, that the autoreactive T cells associated with this
syndrome could be detected in both groups of patients even though
there were no clinical manifestations of GVHD. Perhaps the T
lymphocytes modified the pathogenic potential of the autoreactive
T cells limiting their amplification and reducing the autoaggres-
sive disease from a frank GVHD to a subclinical GVHD. It is clear
in the animal system that these autoreactive T lymphocytes are the
pathogenic T cells that manifest epidermal changes consistent with
GVHD but are exquisitely regulated (Hess et al, 2000). Analysis
of the lymphocytotoxicity profiles showed that the majority of the
patients (76%), independent of their GVHD status, developed
post-transplant lymphocytes capable of inducing lysis of pre-
transplant PHA-lymphoblasts and is in accord with the results of
Miura et al (2000). NK activity was also increased in patients who
developed cutaneous grade II autologous GVHD. An increase in
NK-cells has been reported in the occurrence of GVHD (Ghayur et
al, 1987). Of potential importance in this study is the enhanced
targeting of the T47D breast cancer cell line that may provide for
antitumour immune activity. This enhanced targeting might be
simply explained by the fact that this cell line may just be more
susceptible to lysis. On the other hand, the T47D cells do express
high levels of MHC class II-invariant chain peptide complexes
leading to immune recognition by the CD8+ autoreactive T cells
(Hess et al, 1997). 
In the previously reported phase I trial (Kennedy et al, 1994),
with a median follow-up of nearly 7    years, the OS is 15% with a
6% DFS. With a median time to follow-up of 2  years in the
present study, the OS is 58% with a 26% DFS, independent of the
induction of cutaneous GVHD grade II. Considering the fact that
the majority of the patients in the present study received treatment
for stage IV disease, the survival percentages are certainly not less
favourable than reported after high-dose chemotherapy alone
(Antman et al, 1997). A possible explanation for the absence of a
significant improvement in outcome might be that the autoreactive
cytotoxic T-lymphocytes, while recognizing MHC class II deter-
minants on a wide variety of tissues, do not preferentially target
the tumour cells. This could limit the number of effector cells that
can lyse the tumour cells. In addition, there may be insufficient
amplification of the effector CD8+-T cell population considering
that regulatory T cells may be transferred with the PBPCs.
Currently, the role of CD34† stem cell selection (with the concur-
rent elimination of peripheral T cells) is under investigation. 
In conclusion, administration of CsA and IFN-γ following high-
dose chemotherapy in advanced breast cancer results in the induc-
tion of cutaneous GVHD grade II in a third of the patients without
substantial increase of treatment-related morbidity. Autocytotoxic
effector cells occur in the majority of patients and these cells may
be equally important for an anti-tumour effect in a minimal
residual disease setting or in a setting of very limited tumour
burden. Therefore, in view of the fact minimal residual disease is
the optimal condition to evaluate immunomodulation strategies,
investigating the present treatment approach in the adjuvant
setting seems appropriate. 
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